KAHER
JNMC Women’s & Children’s Health Research Unit
Department of Skin & VD
Research Projects
State – Completed
| Sl No | Principal Investigator | Co-Principal Investigator | Title of the Project | Funding Agency | Duration (From-To) | Clinical Trial Registration Details if any | Status |
| 1 | Dr. Snehal Lunge | A multicentric, assessor-blind , randomized, active controlled, parallel design study comparing efficacy and safety of clobetasol propionate topic foam 0.05%vs. clobetasol propionate lotion 0.05% in patients with mild to moderate plaque type psoriasis (scalp and non scalp) | Torrent Pharmaceutical Ltd. | 2018-2019 | Completed |
Research Projects – Industry Sponsored Clinical Trials
ONGOING
| Sl No | Principal Investigator | Co-Principal Investigator | Title of the Project | Funding Agency | Duration (From-To) | Clinical Trial Registration Details if any | Status |
| 1 | Dr. Shivakumar Patil | A Multicenter, randomized, double-blind,active and placebo controlled study to investigate the efficacy and safety of ligelizumab in the treatment of chronic spontaneous urticaria in adolescents and adults inadequately controlled with H1 anti histamines. | NOVARTIS | 2019 Onwards | Ongoing | ||
| 2 | Dr. Shivakumar Patil | A Multicentre, Randomised, Double-Blind, Double-Dummy, Three Arm, PlaceboControlled, Parallel Adaptive PhaseIII Clinical StudytoEvaluate the Efficacy and Safety of Dimethyl Fumarate Gastro Resistant Hard Capsule of Alvogen Malta (Out-Licensing) Ltd with Fumaderm®Gastro-Resistant Tablet of Biogen GmbHin Subjects with Moderate to Severe Chronic Plaque Psoriasis | Alvogen Malta | 2021 | Ongoing |
COMPLETED
| Sl No | Principal Investigator | Co-Principal Investigator | Title of the Project | Funding Agency | Duration (From-To) | Clinical Trial Registration Details if any | Status |
| 1 | Dr. Shivakumar Patil | Comparative Efficacy, Safety & Tolerability of fixed dose combination of Cephalexin Extended release (375 mg) & clavulanate potassium (125 mg) tables with cephalexin extended release (375 mg) Tablets in the treatment of Uncomplicated skin & soft tissue infections – A Randomized, Double-blind study | Ranbaxy Laboratories LimitedResearch and Development, Medical Affairs & Clinical Research Sector 18, IFFCO Road, Udyog Vihar Industrial Area, Gurgaon, Haryana – 122 015 | 2013-2014 | Completed | ||
| 2 | Dr. Shivakumar Patil | An open-lable, single arm and multu-centered study to evaluate the efficacy, safety and tolerability of lipid based tacrolimus ointment 0.1% of Intas Pharmaceuticals Limited, India in patients of oral lichen planus | INTAS | 2018-2019 | Completed | ||
| 3 | Dr. Shivakumar Patil | A Randamized, double blind, multicenter, three-arm, parallel, placebo-controlled, clinical study to evaluate the bioequivalence using clinical endpoint of clindamycin phosphate 1.2% and benzoyl peroxice 5% Gel (Encube ethicals private limited, India) to DUAC (R) gel (Clindamycin phosphate 1.2% and Benzoyl peroxide 5% Gel) (Stiefel Laboratories, Inc, Research Triangle Park, NC 27709) in subjects with Acne Vulgaris | ENCUBE | 2018-2019 | Completed | ||
| 4 | Dr. Shivakumar Patil | A Multicenter comparative randomized double-blind study of the efficacy and safety of BCD-057 (INN: Adalimumab, CJSC BIOCAD, Russia) and Humira@ (INN: Adalimumab, Vetter Pharma) in patients with moderate to severe plaque psoriasis | BIOCAD | 2017-2020 | Completed |